The detection and quantification of disseminated tumor cells (DTC) present in the bone marrow (BM), peripheral blood (PB) and apheresis products (AP) are becoming increasingly significant in the treatment of cancer patients. Three different applications are implemented in the clinical practice of pediatric and adult solid tumor patients: (1) the identification of tumor cells in the BM and PB at diagnosis; (2) the response of occult tumor cells to high-dose chemotherapy; and (3) the presence of tumor cells in the autograft. In solid tumors the clinical significance of DTCs at diagnosis or during the course of the disease, usually termed minimal residual disease (MRD) testing, is still under debate. These indistinct results are mainly due to methodical reasons. Therefore, a fully automated system (RCDetect/metafer) combining the detection of 'tumorspecific' immunological features together with 'tumor-typical' DNA aberrations has been developed allowing the unambiguous visualization of tumor cells in a hematopoietic surrounding.
There is still an ongoing debate whether or not neuroblastoma (NB) patients with localized disease show disseminated tumor cells in the bone marrow (BM) at diagnosis. Moss and coworkers 1 observed tumor cell infiltrates in 34% of the stage I, II and III patients with immunocytochemical (ICC) approaches. They also found a correlation between the presence of DTCs and unfavorable outcome. PCR techniques also disclosed positive reactions in bone marrow samples from patients with localized disease. 2 Data generated with a fluorescence-based detection system identified only one out of 128 NB patients with localized/regional disease (stages 1, 2A, 2B and 3) with a genetically verified tumor cell infiltrate (Méhes et al, submitted) .
Bone marrow involvement in patients with localized epithelial tumors, best studied in breast carcinoma (BC) patients, were found in the range of 23% to 82% using PCR approaches 3 or alkaline phosphatase-based cytokeratin (CK) detection for example. 4 So far, these results cannot be reproduced by using a fluorescence-based detection of CK combined with a genetic analysis of doubtful cells. 15, 16 Despite the fact that BM samples from only 45 patients with stage 1 or 2 were analyzed, these data clearly indicate that DTC data have to be analyzed critically and quality control studies especially on methodical issues have to be undertaken in order to obtain comparable results.
The response testing to chemotherapy turned out to be of clinical relevance in pediatric ALL patients especially. 5 Also, in stage 4 neuroblastoma patients with genetically aggressive tumors, we observed that the delayed tumor cell clearance of the bone marrow indicated an unfavorable outcome. Rapid bone marrow clearance seems to be associated with a the exact time points when to measure the response are still unknown. Whether this finding, which was made on a limited number of patients, holds true for larger groups of patients, and also the question of whether all genetic subtypes behave in the same way, awaits further studies.
Hematopoietic reconstitution with autologous cells after high-dose chemotherapy in the course of autologous stem cell transplantation for the treatment of solid tumor patients has highlighted the concerns about tumor cell contamination of the autograft. Indirect evidence that tumor cells are responsible for the post-transplant relapse are provided by Ref. 6 . In addition, the presence of tumor cells in the autograft has been correlated with an unfavorable post-transplant outcome in neuroblastoma. 7 A number of strategies allow the identification and estimation of the number of disseminated tumor cells in the hematopoietic system or blood products. Most methods are indirect approaches detecting either genes expressed predominantly or exclusively by tumor cells (eg tyrosine hydroxylase in neuroblastomas, cytokeratin in breast carcinomas) or m-RNAs from gene fusion products as a result of reciprocal translocations (eg bcr/abl in CML patients or EWS/FLI1 in Ewing tumors).
Although the rearranged gene product can be detected by RT-PCR techniques at a high sensitivity, these methods have the disadvantage of false positive results most often caused by contamination. In addition, physiological differences in the expression level of a certain gene product can also obscure the picture. This is especially difficult when analyzing RNA molecules, which although predominantly expressed in the target cell, can also be expressed under certain circumstances by non-neoplastic cells; best exemplified are these false positive results in BM samples from healthy individuals. Here, the number of positive results reaches up to 100% of the samples tested. 8 Furthermore, translocation-specific gene products can also be influenced by physiological conditions or even application of certain drugs. 9 Flow cytometric analyses of rare tumor cells rely on automatic detection of immunofluorescence-labeled antibodies. Besides the use of multiparameter analysis and the high speed of these assays, the sensitivity level is rarely below 1 target cell in 10 −4 MNCs. In addition, non-tumor cells may stain unspecifically and cell morphology cannot be assessed. Only combinations with, for example, PCR techniques can verify the genetic make up of the target cells. 10 Culture techniques for DTC detection are virtually the only assays that provide information on the viability and clonogenicity of rare tumor cells. Daxter-type and agarose-based clonogenic assays are in use. 11 The disadvantages are contamination problems, lack of tumor cell growth besides the presence of vital tumor cells, technical difficulties and time requirements, all of which render culture methods not feasible as a routine method.
Until recently, the direct visualization of tumor cells in the The detection of specific gene rearrangements resulting from tumor-typical translocations and other tumortypical aberrations can be performed by FISH on the DNA level. Besides the high specificity of this method the high sensitivity needed for DTC detection can usually not be achieved.
To circumvent the lack of specificity inherent to ICC techniques, a combination of the immunolgical information with a second tumor-typical marker is essential. This can be achieved either by the introduction of a second or third immunological stain or, ideally, by a combination of an immunological procedure and the detection of a tumor-typical genetic aberration. The demonstration of both the immunological profile and the genetic information on the same cells achieves the high sensitivity of the first technique and the high specificity of FISH techniques. Basically, these two pieces of information can be monitored simultaneously or sequentially. Simultaneous approaches detecting changes on the DNA level and specific cell surface or intercellular antigens are difficult to undertake on a routine basis as these two technological approaches use different pretreatment conditions. On the other hand, a sequential demonstration of genetic aberrations and phenotypic information is difficult to perform on rare cells as it is virtually impossible to relocate these cells without any automatic relocation system. Recently, we were able to introduce an automatic system (RCDetect/metafer; MetaSystems, Altlussheim, Germany) which has been developed to sequentially identify different cell markers on rare tumor cells. Four major goals can be achieved using this automatic system: (1) a high sensitivity can be reached as demonstrated by spiking experiments performed with neuroblastoma cells and breast carcinoma cells. All cells intermixed with normal BM or PB cells could be recovered (Mehes et al in press). Thus we can conclude that: (1) the sensitivity of this method is restricted only by the number of cells available for analysis; (2) the specificity of the recognition system is given by the fact that additional features typical for the tumor cell -either immunological or, even better, genetic aberrations can be simultaneously and/or sequentially demonstrated; in addition, (3) a reliable and exact quantification of all cells (hematopoietic and tumor cells) is possible; and (4) multi-parameter analyses of different cell features, so far only restricted to flow cytometric methods, are possible and functional characterization of rare tumor cells can be studied (Ki-67, apoptosis-related molecules, or multi-drug resistance molecules). Besides the detection of tumor-typical immunostains such as GD2, CD99 and cytokeratin, leukemia-specific antigens CD34, CD19 etc the tumor/leukemia associated genetic aberrations can be identified by the use of FISH analysis as well. An example of a combined immunological and genetic visualization of a tumor cell is given in Figure 1 . A breast carcinoma cell was characterized by a double color immunofluorescence staining with cytokeratin and mucin. After automatic relocation of the same cell a genetic visualization of the tumor typical genetic aberrations was undertaken.
One of the most crucial questions, detecting DTCs in the hematopoetic system is the analysis of their functional status. PCR approaches but also ICC methods cannot discriminate between intact and dead cells or cell fragments, possibly entrapped into phagocytic cells. Thus, studies should include tests on the proliferation capacity, expression of drug resistance-associated genes and occurrence of apoptosis. So far, only very limited information on the functional status of DTC exists. In BC patients it was demonstrated that DTCs show a dormant state of cell growth indicated by little Ki-67 expression. 13 Data on neuroblastoma patients on the other hand indicate that disseminated tumor cells show a relatively high Ki-67 expression with a median value of 30% in untreated tumor patients (Mehes unpublished) and this figure is in line with the Ki-67 expression found in untreated neuroblastic tumors. 14 In summary, this new detection method allows an accurate diagnosis, exact quantification, and functional characterization of low tumor cell infiltrates in the hematopoietic system besides offering an ideal way to monitor the response of the tumor cells to cytotoxic treatment. 
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